TrialPanorama/TrialPanorama-database huggingface dataset:
Study: NCT02960165

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Virtual interface group
Description: First practice on virtual interface in order to evaluate the improvement and its influence on real interface performance (second practice).

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Virtual interface group
Description: First practice on virtual interface in order to evaluate the improvement and its influence on real interface performance (second practice).

Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: Real interface group
Description: First practice on real interface in order to evaluate the improvement and its influence on virtual interface performance (second practice).

Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: Real interface group
Description: First practice on real interface in order to evaluate the improvement and its influence on virtual interface performance (second practice).
Study: NCT06206577

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Horizontal ridge augmentation by symphyseal bone block placed and fixed buccally as onlay graft
Description: autogenous bone block harvested from chin area using piezosurgery and fixed buccally in deficient area with fixation screws

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Horizontal ridge augmentation by symphyseal bone block interpositioned in space created between buccal and lingual cortex as inlay graft
Description: autogenous bone block harvested from chin area using piezosurgery and fixed in bone split created at deficient area with fixation screws
Study: NCT02949193

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: evogliptin
Description: evogliptin 5mg tablet qd + placebo tablet matching to sitagliptin 100mg

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Sitagliptin
Description: sitagliptin 100 mg tablet qd + placebo tablet matching to evogliptin 5mg
Study: NCT00068393

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Doxorubicin
Description: Doxorubicin: 50 mg/m² IV slow push followed by gemcitabine 1500 mg/m² IV infusion over 30 minutes on day 1. Cycles repeat every 2 weeks.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Gemcitabine
Description: Doxorubicin: 50 mg/m² IV slow push followed by gemcitabine 1500 mg/m² IV infusion over 30 minutes on day 1. Cycles repeat every 2 weeks.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: G-CSF (granulocyte-colony stimulating factor)
Description: Patients will receive G-CSF at a subcutaneous dose of 5mcg/kg/day on days 2 or 3 to 10 or neulasta at a dose of 6mg on day 2. Growth factor must be administered as close as possible to 24 hours after the completion of chemotherapy. It is recommended that neulasta be administered only on day 2 due to its prolonged half-life.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Neulasta
Description: Patients will receive G-CSF at a subcutaneous dose of 5mcg/kg/day on days 2 or 3 to 10 or neulasta at a dose of 6mg on day 2. Growth factor must be administered as close as possible to 24 hours after the completion of chemotherapy. It is recommended that neulasta be administered only on day 2 due to its prolonged half-life.
Study: NCT02320058

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Ipilimumab

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Nivolumab
Study: NCT02878564

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Praziquantel
Description: 40 mg/kg, PO (orally administered tablets)
Study: NCT05730959

Intervention type: DEVICE
Group type: OTHER
Intervention: Sacral nerve modulation
Description: Implant of nerve stimulator
Study: NCT01910545

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: OTS167IV
Study: NCT03866083

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Extracorporeal Cytokine hemadsorption therapy
Description: Hemoperfusion will be carried out for one session within 12 hours for all randomized patient using the adsorption columns for Jianfan Biotechnology Co., Zhuhai, China). The hemoperfusion apparatus will be connected in front of the hemodialyzer in series.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Standard Medical Treatment
Description: Standard Medical Treatment

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Standard Medical Treatment
Description: Standard Medical Treatment
Study: NCT03830684

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Baicalein Tablets 400mg
Description: 4 Baicalein Tablets and 2 placebo per time, three times a day

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Baicalein Tablets 600mg
Description: 6 Baicalein Tablets per time, three times a day

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: blank control 0mg
Description: 6 placebo per time, three times a day
Study: NCT04724343

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Triptorelin acetate
Description: 0.05-0.1 mg subcutaneously (SC) once daily from the mid-luteal phase (day 21) of the cycle until the day of ovulation triggering.
Study: NCT05982028

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Minimally invasive pit-picking surgery
Description: Midline pits and secondary fistula openings were probed to determine the direction and length of any associated sinus tracts, followed by an excision with a 3 or 5 mm punch biopsy needle, depending on the size of the pit. A 2 cm lateral incision was made parallel to the pilonidal cyst. Hair and granulations within the sinus tracts were removed, and the cyst cavity was drained through the incision. Nonabsorbable monofilament sutures were used to close the excisional wounds of the pits and secondary fistula. Once haemostasis was achieved, the wound was covered with a sterile gauze with 10 % povidone-iodine solution.
Study: NCT04724343

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Cetrorelix
Description: 0.25 mg subcutaneously (SC) once daily starting from the day detecting a leading follicle diameter ≥ 14 mm until the day of ovulation triggering.

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: recombinant-FSH or recombinant-FSH + human Menopausal Gonadotropin
Description: Dosage adjustment according to the ovarian response.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: recombinant-FSH or recombinant-FSH + human Menopausal Gonadotropin
Description: Dosage adjustment according to the ovarian response.

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Human Chorionic Gonadotropin (hCG)
Description: Ovulation will be triggered by the administration of 10,000 IU of Human Chorionic Gonadotropin (hCG) when at least three follicles become more than 16-17 mm.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Human Chorionic Gonadotropin (hCG)
Description: Ovulation will be triggered by the administration of 10,000 IU of Human Chorionic Gonadotropin (hCG) when at least three follicles become more than 16-17 mm.
Study: NCT04293029

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: SHR0302
Description: SHR0302

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: SHR0302
Description: SHR0302

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: SHR0302
Description: SHR0302
Study: NCT04106895

Intervention type: DRUG
Intervention: Fibryga
Description: Fibryga
Study: NCT02538887

Intervention type: DEVICE
Intervention: Radio Frequency Surgical Detection
Study: NCT03099213

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: RAMIPRIL HOE498
Description: Pharmaceutical form:Tablet Route of administration: Oral
Study: NCT03335007

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Aceclofenac
Description: Aceclofenac 100 mg tablet given one hour before starting the root canal treatment

Intervention type: OTHER
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Placebo tablet given one hour before starting the root canal treatment
Study: NCT03995589

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Walking
Description: Technology-guided semi-supervised walking therapy

Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Control
Description: Go Home and Walk advice
Study: NCT02357095

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: monitoring
Description: uterine artery chemo-embolization combined with suction curettage under different monitoring methods,such as hysteroscopic monitoring,ultrasonography monitoring and no monitoring

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: monitoring
Description: uterine artery chemo-embolization combined with suction curettage under different monitoring methods,such as hysteroscopic monitoring,ultrasonography monitoring and no monitoring

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: monitoring
Description: uterine artery chemo-embolization combined with suction curettage under different monitoring methods,such as hysteroscopic monitoring,ultrasonography monitoring and no monitoring
Study: NCT03341143

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Fecal Microbiota Transplant with Pembrolizumab
Description: FMT is a procedure in which fecal matter or stool is collected from a tested donor, mixed with a saline or other solution, strained and infused into the colon by doing a colonoscopy. The FMT consists of introducing normal bacterial flora contained in stool collected from a donor into your small intestine. In this case, the donor is patient with advanced melanoma who has been treated with a PD-1 inhibitor (nivolumab or pembrolizumab) and has been rendered disease-free as a result. The FMT will be performed on Cycle 1 Day 1.~Pembrolizumab, 200mg, through an IV over 30 minutes on Cycle 1 Day 1 (same day as the FMT, and then again on Day 1 of each 21-day cycle for an additional 3 cycles (Cycles 2 - 4).
Study: NCT00078975

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: gemcitabine hydrochloride

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: triapine
Study: NCT02383368

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: ASP4132
Description: oral

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: ASP4132
Description: oral
Study: NCT03526536

Intervention type: DRUG
Group type: OTHER
Intervention: IV Novolin R human insulin
Description: Novolin R human insulin, Novo Nordisk Inc. Plainsboro, NJ

Intervention type: DRUG
Group type: OTHER
Intervention: IV Novolin R human insulin
Description: Novolin R human insulin, Novo Nordisk Inc. Plainsboro, NJ
Study: NCT02779699

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: AL2846
Description: AL2846 p.o. qd
Study: NCT01862263

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Vildagliptin
Description: Orally active and highly selective inhibitor of DPP-4

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Insulin
Description: Long- acting human insulin analog indicated to improve glycemic control

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Insulin
Description: Long- acting human insulin analog indicated to improve glycemic control

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Matching placebo of vildagliptin
Study: NCT01571999

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Inhaled GSK573719
Description: All subjects will receive a single dose of GSK573719 (125mcg) in treatment period 1

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Inhaled GSK573719
Description: All subjects will receive a single dose of GSK573719 (125mcg) in treatment period 1

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Inhaled GSK573719/vilanterol
Description: All subjects will receive a single dose of GSK573719 (125mcg)/vilanterol (25mcg) in treatment period 2

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Inhaled GSK573719/vilanterol
Description: All subjects will receive a single dose of GSK573719 (125mcg)/vilanterol (25mcg) in treatment period 2
Study: NCT01004640

Intervention type: GENETIC
Intervention: DNA analysis

Intervention type: GENETIC
Intervention: Southern blotting
Study: NCT04079530

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: K-877 IR 0.2 mg/day
Description: K-877 IR 0.1 mg tablet

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: K-877 IR 0.2 mg/day
Description: K-877 IR 0.1 mg tablet

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: K-877 IR 0.2 mg/day
Description: K-877 IR 0.1 mg tablet

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: K-877 IR 0.2 mg/day
Description: K-877 IR 0.1 mg tablet

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: K-877 CR 0.4 mg/day
Description: K-877 CR 0.4 mg tablet

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: K-877 CR 0.4 mg/day
Description: K-877 CR 0.4 mg tablet

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: K-877 CR 0.4 mg/day
Description: K-877 CR 0.4 mg tablet

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: K-877 CR 0.4 mg/day
Description: K-877 CR 0.4 mg tablet

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: K-877 CR 0.4 mg/day
Description: K-877 CR 0.4 mg tablet

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: K-877 CR 0.4 mg/day
Description: K-877 CR 0.4 mg tablet

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: K-877 CR 0.4 mg/day
Description: K-877 CR 0.4 mg tablet

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: K-877 CR 0.4 mg/day
Description: K-877 CR 0.4 mg tablet

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: K-877 CR 0.8 mg/day
Description: Two K-877 CR 0.4 mg tablet

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: K-877 CR 0.8 mg/day
Description: Two K-877 CR 0.4 mg tablet

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: K-877 CR 0.8 mg/day
Description: Two K-877 CR 0.4 mg tablet

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: K-877 CR 0.8 mg/day
Description: Two K-877 CR 0.4 mg tablet

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: K-877 CR 0.8 mg/day
Description: Two K-877 CR 0.4 mg tablet

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: K-877 CR 0.8 mg/day
Description: Two K-877 CR 0.4 mg tablet

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: K-877 CR 0.8 mg/day
Description: Two K-877 CR 0.4 mg tablet

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: K-877 CR 0.8 mg/day
Description: Two K-877 CR 0.4 mg tablet
Study: NCT04473378

Intervention type: DEVICE
Intervention: FreeStyle Libre Pro
Description: The device uses patches that attach to the skin on the back of the arm to measure blood sugar changes for the duration of the chemotherapy course.
Study: NCT03743649

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Haloperidol
Description: Given IV

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Haloperidol
Description: Given IV

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Lorazepam
Description: Given IV

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Lorazepam
Description: Given IV

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Lorazepam
Description: Given IV
Study: NCT01004640

Intervention type: GENETIC
Intervention: cytogenetic analysis
Description: Correlative studies

Intervention type: GENETIC
Intervention: polymerase chain reaction
Study: NCT03743649

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Placebo
Description: Given IV

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Placebo
Description: Given IV
Study: NCT03805984

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: INO-4500
Description: INO-4500 will be administered ID on Day 0 and Week 4.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: INO-4500
Description: INO-4500 will be administered ID on Day 0 and Week 4.
Study: NCT03743649

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Placebo
Description: Given IV

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Quality-of-Life Assessment
Description: Ancillary studies

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Quality-of-Life Assessment
Description: Ancillary studies

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Quality-of-Life Assessment
Description: Ancillary studies
Study: NCT03805984

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Placebo will be administered ID on Day 0 and Week 4.

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Placebo will be administered ID on Day 0 and Week 4.

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: CELLECTRA® 2000
Description: EP using the CELLECTRA® 2000 device will be administered following ID drug administration.

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: CELLECTRA® 2000
Description: EP using the CELLECTRA® 2000 device will be administered following ID drug administration.

Intervention type: DEVICE
Group type: PLACEBO_COMPARATOR
Intervention: CELLECTRA® 2000
Description: EP using the CELLECTRA® 2000 device will be administered following ID drug administration.

Intervention type: DEVICE
Group type: PLACEBO_COMPARATOR
Intervention: CELLECTRA® 2000
Description: EP using the CELLECTRA® 2000 device will be administered following ID drug administration.
Study: NCT02135107

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Rabeprazole
Description: Rabeprazole 10 mg was administered orally twice daily during the treatment period for 8 weeks (unblinded).

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Rabeprazole
Description: Rabeprazole 20 mg was administered orally twice daily during the treatment period for 8 weeks (unblinded).

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Rabeprazole
Description: Rabeprazole 10 mg or 20 mg were administered orally twice daily during the treatment period (unblinded), and 10 mg was administered once daily during the maintenance period (double-blind).

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Rabeprazole
Description: Rabeprazole 10 or 20 mg were administered orally twice daily during the treatment period (unblinded), and 10 mg was administered twice daily during the maintenance period (double-blind).
Study: NCT01172496

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: treprostinil diethanolamine
Description: Subjects will be administered a 1 mg dose of treprostinil diethanolamine as a single tablet, and treprostinil diethanolamine oral solution 0.25 mg dose every 2 hours for four doses (1 mg total).

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: treprostinil diethanolamine
Description: Subjects will be administered a 1 mg dose of treprostinil diethanolamine as a single tablet, and treprostinil diethanolamine oral solution 0.25 mg dose every 2 hours for four doses (1 mg total).
Study: NCT02980419

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: presentation of visual and vestibular stimuli
Description: In each participant the investigators will assess verticality perception in whole-body upright position by use of the SVV, the SPV and the SHV after static roll-tilt at ±90deg over 5min. Measurements will be obtained on a motor-driven turntable and two different roll-tilt positions will be applied (±90°). A visual line (SVV), a rod (SHV) or the turntable itself will be adjusted to indicate perceived direction of vertical. A total of three measuring sessions, each lasting about 60 minutes are scheduled.
Study: NCT03764826

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: CAABT
Description: The sound generators with CAABT will be used 15 min each session, three times a day

Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: TMT
Description: The sound generators with TMT will be used 15 min each session, three times a day
Study: NCT02094976

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Jackson surgical table
Description: After standard total intravenous anesthesia using propofol and remifentanil continous infusion, patients were turned to the prone position on a Jackson table with two padded supports on each side. The supports were positioned under the lateral chest and at the iliac crest.

Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: Wilson frame
Description: After standard total intravenous anesthesia using propofol and remifentanil continous infusion, patients were turned to the prone position on a Wilson frame. The supports were positioned vertically from shoulder to iliac crest.

Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: Chest roll
Description: After standard total intravenous anesthesia using propofol and remifentanil continous infusion, patients were turned to the prone position on a chest roll. The supports were positioned vertically from shoulder to iliac crest.
Study: NCT00657033

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Levitra (Vardenafil, BAY38-9456)
Description: BAY 38-9456 (Vardenafil) will be supplied as 5 mg tablets, 10 mg tablets, and 20 mg tablets.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Placebo
Description: Identical placebo tablets will be matched for each vardenafil dosage and will be indistinguishable from active treatment
Study: NCT04563975

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Toripalimab
Description: Toripalimab，240mg，d1，Intravenous Infusion，q3w

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Docetaxel
Description: Docetaxel，60-75mg/m2，d8 and d15，Intravenous Infusion，q3w

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: nab-paclitaxel
Description: nab-paclitaxel，125mg/m2，d1 and d 8，Intravenous Infusion，q3w
Study: NCT02009397

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Ipilimumab

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: GM-CSF
Study: NCT01253551

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Treatment sequence AB
Description: Treatment A: telaprevir 750 mg every 8 hours on Days 1 to 6, with a morning dose on Day 7. Treatment B: raltegravir 400 mg twice a day on Days 1 to 10 and telaprevir 750 mg every 8 hours on Days 5 to 10, with a morning dose of raltegravir, and a morning and afternoon dose of telaprevir on Day 11.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Treatment sequence BA
Description: Treatment A: telaprevir 750 mg every 8 hours on Days 1 to 6, with a morning dose on Day 7. Treatment B: raltegravir 400 mg twice a day on Days 1 to 10 and telaprevir 750 mg every 8 hours on Days 5 to 10, with a morning dose of raltegravir, and a morning and afternoon dose of telaprevir on Day 11.
Study: NCT04528212

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Glimepiride Tablets
Description: Glimepiride (4 mg) per Day

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: glimepiride plus fenofibrate
Description: Glimepiride (4 mg) plus Fenofibrate (160 mg) per Day

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: glimepiride plus curcumin
Description: Glimepiride (4 mg) plus Curcumin (1100 mg) With 5mg Black Pepper per Day
Study: NCT02315495

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Saxagliptin

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Saxagliptin

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Acarbose

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Acarbose